6-K ·Filed Sep 18, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor the conference webcast for any updates on the Phase 3 pivotal trial for ATH434 in MSA, but this filing itself provides no new catalyst.
Latest settled — T+20d
ATHE ▼ -32.99% at T+20d
NEUTRAL call -32.99% · α vs SPY -33.20% · entry $3.91 → $2.62
Latest observation: T+25 -38.68% FF3 residual α
T+1d
-3.32%
call -3.32% · α -4.88%
$3.78
settled 5w ago
T+5d
-6.14%
call -6.14% · α -7.41%
$3.67
settled 5w ago
T+20d
-32.99%
call -32.99% · α -33.20%
$2.62
settled 11d ago
T+60d
Pending
in 7w
Price Chart
Loading chart...
Executive Summary
Alterity Therapeutics filed a 6-K announcing that Non-Executive Director Lawrence Gozlan will present at the ASX SMIDcaps Conference on September 23, 2026. This is a routine investor relations event with no new financial or clinical data disclosed.
Key Facts
- Lawrence Gozlan, Non-Executive Director, will present at the ASX SMIDcaps Conference on September 23, 2026 at 1:55 p.m. AEST.
- No new financial results, clinical data, or material operational updates were provided.
- The filing incorporates by reference existing registration statements on Form S-8 and Form F-3.
Financial Impact
No financial impact; routine conference presentation announcement.
Risk Factors
- No new information reduces the likelihood of a near-term stock-moving event from this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-030702 |
| Exhibit: ex_1017645.htm | 0001437749-26-030702 |
| Document: 0001437749-26-030702-index-headers.html | 0001437749-26-030702 |
| Document: 0001437749-26-030702-index.html | 0001437749-26-030702 |
| Document: 0001437749-26-030702.txt | 0001437749-26-030702 |
42 reports for ATHE
67% Hit rate @ T+60 Went positive at some point 10 of 10 best @ T+20▲ +27.97%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 21d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
Showing 10 of 42
US Market Status
Market Closed — Opens in 2h 32m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers